Hypomethylating Agents plus Venetoclax as Compared with Intensive Chemotherapy in Patients with AML
Mené sur 172 patients atteints d'une leucémie myéloïde aiguë (âge médian : 64 ans ; durée médiane de suivi : 21,9 mois), cet essai de phase II compare l'efficacité, du point de vue de la survie sans événement, et la toxicité d'une chimiothérapie d'induction et d'un traitement combinant azacitidine et vénétoclax
I first treated a patient with leukemia with the so-called “7+3” regimen (a 7-day continuous infusion of cytarabine plus three daily infusions of an anthracycline, usually daunorubicin)1 more than 50 years ago during my residency. To be candid, I had little understanding of what I was doing but was aware that skeptics characterized daunorubicin as the “red death.” But they were wrong. Associated with advancements in platelet transfusion, venous access, and antiemetic, antibiotic, and antifungal therapies, this intensive chemotherapy led to high percentages of patients with remission and substantial percentages with cure in subgroups of patients with acute myeloid leukemia . . .
New England Journal of Medicine , éditorial, 2026